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Background: In the chronically inflamed rabbit small intestine, brush border membrane (BBM) Na-glutamine
co-transport is inhibited in villus cells (mediated by B0AT1), while it is stimulated in crypt cells (mediated by
SN2/SNAT5). How mast cells, known to be enhanced in the chronically inflamed intestine, may regulate B0AT1
in villus and SN2/SNAT5 in crypt cell is unknown. Thus, the aim of the present study is to determine the regulation of
B0AT1 and SN2/SNAT5 by mast cells during chronic enteritis.
Methods: Chronic intestinal inflammation was induced in male rabbits with intra-gastric inoculation of Eimeria magna
oocytes. Rabbits with chronic inflammation were treated with ketotifen (10 mg/day) or saline (Placebo) for 2 days. Villus
and crypts cells were isolated from the rabbit intestine using the Ca++ chelation technique. Na/K-ATPase activity was
measured as Pi from cellular homogenate. BBM vesicles (BBMV) were prepared from villus and crypt cells and uptake
studies were performed using rapid filtration technique with 3H-Glutamine. Western blot analyses were done using B0AT1
and SN2 specific antibodies.
Results: In villus cells, Na-glutamine co-transport inhibition observed during inflammation was completely reversed by
ketotifen, a mast cell stabilizer. In contrast, in crypt cells, Na-glutamine co-transport stimulation was reversed to normal
levels by ketotifen. Kinetic studies demonstrated that ketotifen reversed the inhibition of B0AT1 in villus cells by restoring
co-transporter numbers in the BBM, whereas the stimulation of SN2/SNAT5 in crypts cells was reversed secondary
to restoration of affinity of the co-transporter. Western blot analysis showed that ketotifen restored immune-reactive levels
of B0AT1 in villus cells, while SN2/SNAT5 levels from crypts cell remained unchanged.
Conclusion: In the present study we demonstrate that mast cells likely function as a common upstream immune
pathway regulator of the Na-dependent glutamine co-transporters, B0AT1 in villus cells and SN2 in crypts cells that are
uniquely altered in the chronically inflamed small intestine.
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Glutamine, the most abundant amino acid plays a vital role
in the regulation of cell specific processes including metab-
olism (e.g., oxidative fuel, gluconeogenic precursor, and
lipogenic precursor), cell integrity (apoptosis, cell prolifera-
tion), protein synthesis and degradation, contractile protein* Correspondence: sundaramu@marshall.edu
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unless otherwise stated.mass, redox potential, respiratory burst, insulin resistance,
insulin secretion, and extracellular matrix synthesis [1-5].
In addition, glutamine is not only the primary source of
energy for intestinal cells, but has also been shown to play
an important role in maintaining mucosal health and integ-
rity during gastrointestinal disorders [3,6].
As the principal nutrient for the intestinal epithelium,
glutamine is primarily assimilated through Na-dependent
glutamine co-transporters expressed on the brush border
membrane (BBM) of enterocytes in rabbit small intestine
[7,8]. Previously we also demonstrated that Na-glutaminehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(SLC6A19) [7] in villus cells while it is mediated by
SN2/SNAT5 (SLC38A5) in crypt cells [8]. Our studies
have also shown extensively the functional and molecu-
lar properties of these transporters, including substrate
specificity, kinetic properties, and protein expression.
Based on our observations, we suggested that glutamine
uptake was approximately four times greater in villus
cells as compared to crypt cells, standardized for BBM
protein of these cells [7,8]. Further, in the chronically
inflamed rabbit small intestine we demonstrated that
B0AT1 was inhibited in villus cells while SN2/SNAT5 was
stimulated in crypt cells [9]. Furthermore, we showed that
the mechanism of inhibition of B0AT1 was secondary to a
reduction in the number of BBM co-transporters whereas
the stimulation of SN2/SNAT5 was secondary to enhanced
affinity of the co-transporter for glutamine.
Over the years there has been increasing awareness in
the pathophysiology of inflammatory bowel disease (IBD)
and the role of various mucosal leukocytes, such as mast
cells, in the pathogenesis of the disease. A marked increase
in the number of mast cells accompanied by elevated de-
granulation of mucosal mast cell chemical mediators and
cytokines such as histamine, substance P and tumor
necrosis factor α have been observed in the mucosa of
the ileum and colon of patients with IBD [10-13]. Also,
regulation of mast cell activation by mast cell stabiliz-
ing agents has been shown to reduce inflammation and
fibrosis of intestinal lesions of the experimental colitis
[14]. However, what is not clear is whether mucosal
mast cells may affect Na-glutamine co-transport during
intestinal inflammation.
The wide variety of immune-inflammatory mediators
known to be endogenously produced in the chronically in-
flamed ileum may, at least in part, have an effect on nutri-
ent transport pathways including Na-glucose, Na-alanine
and Na-taurocholate co-transport [15-18]. Nevertheless, it
is not known whether a given immune-inflammatory
mediator pathway may be responsible for Na-glutamine
co-transport alterations during chronic ileitis, but glu-
cocorticoids, a broad-spectrum immune modulator used
for the treatment of IBD, has been shown to alleviate the al-
terations. We have shown that methylprednisolone reversed
the inhibition of B0AT1 in villus and stimulation of SN2/
SNAT5 in crypt cells during chronic intestine inflammation
[19]. These observations suggest that the alterations in
Na-glutamine co-transport are actively regulated by
immune-inflammatory mediators in the chronically in-
flamed intestine. However, it is not known if mast cell me-
diators may regulate Na-glutamine co-transport activity
during chronic enteritis. Thus, the aim of the present study
was to assess whether stabilization of mast cell membrane
by ketotifen will alleviate the alterations in B0AT1 and/or
SN2/SNAT5 during chronic enteritis.Methods
Animals: induction of chronic inflammation, drug
treatment and cell isolation
Pathogen free New Zealand White male rabbits (Charles
River Laboratories International Inc.) were used for the
study. Four cohorts of animals, 4 animals in each cohort,
were used: normal, inflamed, normal + ketotifen and in-
flamed + ketotifen. Chronic intestinal inflammation was
induced in rabbits by intragastrically inoculating them
with Eimeria magna oocytes as previously reported
[18,20]. Normal and inflamed rabbits that were injected
intramuscularly with saline were used as untreated con-
trols. For drug treatment, normal and inflamed rabbits
were intramuscularly injected with ketotifen (10 mg/kg
body weight), a noncompetitive H1-antihistamine and
mast cell stabilizer, 12 and 13 days post coccidia inocula-
tion and the animals were euthanized on day 14. All ani-
mal handling, treatments and euthanization were carried
out according to the protocol approved by the Institu-
tional Animal Care and Use Committee of West Virginia
University (ACUC protocol # 12–0102).
Villus and crypt cells were isolated from the rabbit
ileum by a calcium chelation technique as previously de-
scribed [18]. Briefly, a 3-ft section of ileum was filled
and incubated with cell isolation buffer (0.15 mM EDTA,
112 mM NaCl, 25 mM NaHCO3, 2.4 mM K2HPO4,
0.4 mM KH2PO4, 2.5 mM L-glutamine, 0.5 mM β-
hydroxybutyrate, and 0.5 mM dithiothreitol; gassed with
95% O2 and 5% CO2, pH 7.4, at 37°C) for 3 min and
gently palpitated for another 3 min to facilitate cell dis-
persion. The buffer was then drained out from the ileal
section, phenylmethylsulfonyl fluoride was added, and
the suspension was centrifuged at 100 g for 3 min. Cells
to be used for BBM vesicle (BBMV) preparation were fro-
zen immediately in liquid nitrogen and stored at −80°C
until required.
β-Hexosaminidase assay
When activated mast cells undergo degranulation they
release a substantial amount of enzymes that mediate
several inflammatory pathways. One such enzyme that is
released is β-Hexosaminidase, the levels of which are es-
timated as an index of mast cell degranulation during
inflammation. In the present study, β-Hexosaminidase
assay was performed as previously reported [21], to detect
mast cell degranulation in vivo. Briefly, enterocytes lysed
with 1% Triton X-100 were incubated with the substrate
solution (P-nitrophenyl-Nacetyl-β-D-glucosaminide from
Sigma, St Louis, MO) in 0.1 M citrate buffer (pH 4.5) for
60 min at 37°C. The reaction was terminated by the
addition of 0.2 M NaOH/0.2 M glycine. Using an enzyme-
linked immunosorbent assay reader, absorbance was
acquired at 405 nm and the results were expressed as
percentage β-Hexosaminidase activity relative to control.
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Na-K-ATPase was measured as Pi liberated [22] in cellular
homogenates from the same amount of cells from all ex-
perimental conditions as previously described [9,18,22].
Enzyme-specific activity was expressed as nanomoles of
Pi released per milligram protein per minute.
Uptake studies in villus and crypt cells
Intact villus and crypt cell uptakes were done using pre-
viously described protocol [9,18]. Briefly, villus or crypt
cells (100 mg wet wt.) were washed and resuspended in
HEPES buffer containing 0.2 mM glutamine, 4.5 mM
KCl, 1.2 mM KH2PO4, 1.0 mM MgSO4, 1.25 mM CaCl2,
20 mM HEPES, and either 130 mM sodium chloride or
choline chloride and was gassed with 100% O2 (pH 7.4
at 37°C). Ten μCi of 3H-glutamine was added to 1 mL of
cell suspension in HEPES buffer and 100 μL aliquots
were removed at 2 minutes and mixed with 1 mL ice-cold
stop solution (choline-HEPES buffer) to stop the uptake.
The mixture was then filtered on 0.65 μm Millipore
(Bedford, MA; HAWP) filters and washed twice with
ice cold-stop solution. The filter was dissolved in 5 mL
Ecoscint and the radioactivity was determined in a
Beckman Coulter LS6500 Scintillation counter.
BBMV preparation and uptake studies
BBMV from rabbit ileal villus and crypt cells were pre-
pared by CaCl2 precipitation and differential centrifuga-
tion as previously described [18]. Uptake studies were
performed by rapid filtration technique [18,20]. Briefly,
5 μL of BBMV resuspended in vesicle medium (100 mM
choline chloride, 0.10 mM MgSO4, 50 mM HEPES-Tris
(pH 7.5), 50 mM mannitol, 50 mM KCl) were voltage
clamped with 10 μM valinomycin and 100 mM carbonyl
cyanide p-(tri-fluoromethoxy) phenyl-hydrozone. The vesi-
cles were then incubated in 95 μL of reaction medium
(50 mM HEPES-Tris buffer (pH 7.5), 0.2 mM glutamine,
20 μCi 3H-glutamine, 0.10 mM MgSO4, 50 mM KCl,
50 mM mannitol, 100 mM of either NaCl or choline chlor-
ide) and at desired time points uptake was arrested by
mixing with ice-cold stop solution of 50 mM HEPES-
Tris buffer (pH 7.5), 0.10 mM MgSO4, 75 mM KCl,
and 100 mM choline chloride. The stopped reaction
mixture was filtered on a 0.45 μm Millipore (HAWP)
filter and washed with 10 mL ice-cold stop solution,
twice. Filters were then dissolved in Ecoscint solution
and radioactivity was determined in a Beckman Coulter
LS6500 Scintillation counter.
Kinetic studies
Na-dependent glutamine uptake was performed as described
above in BBMV from all experimental conditions. Kinetic
parameters were derived from Na-dependent glutamine up-
take at 6 seconds performed at varying concentrations ofextra vesicular glutamine (0.2, 0.5, 1, 5, 10, 25, 50, 75 and
100mM). Uptake values were analyzed for simpleMichaelis-
Menten kinetics using a non-linear regression data analysis
using GraphPad Prism 4 (SanDiego, CA).
Western blot analysis
BBM protein was used for all Western blot experiments.
BBM was solubilized in a buffer consisting of 50 mM
Tris–HCl (pH 7.4), 1% Igepal, 150 mM NaCl, 1 mM
EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, supple-
mented with a mixture of a protease inhibitor (Sigma,
St.Louis, MO). Equal amounts of protein were dena-
tured in a sodium dodecyl sulfate (SDS)/sample buffer
(20 mM Tris pH 7, 12% glycerol, 2% SDS, 0.01% bromo-
phenol blue, and freshly added 1 mM Dithiothreitol) and
separated by electrophoresis on a 4%–20% gradient Gel
(Bio-Rad Laboratories, Hercules, CA). Proteins on the
gel were transferred to a polyvinylidene membrane
which was blocked with 5% dry milk in TBS (20 mM
Tris, pH 7.5, 150 mM NaCl) with 0.1% Tween-20 and
then incubated with a goat polyclonal antibody against
B0AT1, overnight at 4°C followed by incubation with an
anti-goat IgG conjugated to horseradish peroxidase
(Jackson Immunoresearch Laboratories, West Grove,
PA) for an hour at room temperature. For SN2/SNAT5,
a chicken polyclonal antibody against SN2/SNAT5 was
used as the primary antibody and an anti-chicken IgG
was used as the secondary. Both the primary antibodies
were obtained through the custom antibody services
provided by Invitrogen. ECL Western blotting detection
reagent (GE Healthcare Bio-Sciences, Piscataway, NJ)
was used to detect the immobilized protein. The result-
ant chemiluminescence was detected using biomax film
(Kodak, Rochester, NY) and the intensity of the bands
was analyzed by a FluorChem™ instrument (Alpha
Innotech, San Leandro, CA).
Statistical analysis
Data are shown as mean ± SEM in all figures. All individual
uptakes were done in triplicate. The ‘n’ number for any set
of uptake experiments or Western blot analysis refers to
vesicle or isolated cell preparations from different animals.
Data were analyzed using one-way analysis of variance
(ANOVA) to assess the significance between control and
experimental groups by using GraphPad Instat 4 (San
Diego, CA) for statistical analysis and a p value of less than
0.01 was considered significant.
Results
Effects of ketotifen on mast cell β-hexosaminidase in
intestinal mucosa
β-hexosaminidase activity was significantly increased in
enterocytes from the chronically inflamed intestine indi-
cating enhanced degranulation of mast cells. Whereas,
Figure 2 Effect of ketotifen on Na-glutamine co-transport in intact
cells. A, Villus cells. Na-dependent glutamine uptake was determined
as a function of 3H-glutamine uptake in the presence of extracellular
Na minus uptake in the absence of extracellular Na. Na-dependent
glutamine uptake was significantly decreased in villus cells from the
chronically inflamed intestine and treatment with ketotifen reversed
this inhibition. Ketotifen had no effect on Na-glutamine co-transport
in villus cells from the normal intestine. B, Crypt cells. Na-glutamine
co-transport uptake was significantly increased in crypt cells during
chronic intestinal inflammation and treatment with ketotifen reversed
this stimulation. Ketotifen had no effect on Na-glutamine co-transport
in crypt cells from the normal intestine.
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enteritis, β-hexosaminidase release returned to near normal
levels indicating that mast cell degranulation was prevented
(Figure 1).
Effect of ketotifen on Na-glutamine co-transport in intact
villus and crypt cells
Na-glutamine co-transport, which is known to be signifi-
cantly inhibited in the villus cells during chronic intes-
tinal inflammation was completely reversed by ketotifen
treatment (Figure 2A, 84.4 ± 5.3 pmol/mg protein•2 min
in villus cells from inflamed and 156 ± 15.4 from ketoti-
fen + inflamed). Ketotifen did not have any effect in vil-
lus cells from the normal intestine (Figure 2A, 171 ± 5
pmol/mg protein•2 min in normal and 170 ± 12.8 in
ketotifen treated normal villus cells).
In contrast, in crypt cells, Na-glutamine co-transport
which was stimulated during chronic intestinal inflamma-
tion was reversed to near normal levels by ketotifen treat-
ment (Figure 2B, 135 ± 6 pmol/mg protein•2 min in crypts
from inflamed intestine and 66 ± 2 in inflamed + ketotifen).
Here again, ketotifen did not affect Na-glutamine co-
transport in crypt cells isolated from normal animals
treated with ketotifen (Figure 2B, 81 ± 3 pmol/mg pro-
tein•2 min in normal and 82.3 ± 2.6 in normal + ketotifen).
This data shows that ketotifen reverses the inhibition of
Na-glutamine co-transport in villus cells and its stimulation
in crypt cells to their normal levels during chronic enteritis.
Effect of ketotifen on Na-K-ATPase activity in villus and
crypt cells
Basolateral membrane Na-K-ATPase provides the transcel-
lular Na+ gradient required to drive Na-coupled trans-
porters in the BBM. In villus cells from the chronically
inflamed intestine, Na-K-ATPase activity was significantly
inhibited and this inhibition was reversed by treatment with
ketotifen (Figure 3A, 13.5 ± 1.8 nmol/mg protein•min inFigure 1 Effects of ketotifen on β-hexosaminidase activity in enterocytes.
β-hexosaminidase activity normalized to 1 in enterocytes and expressed
as % relative to control. β-hexosaminidase activity was significantly
increased in enterocytes from the chronically inflamed intestine when
compared to controls. Ketotifen treatment restored β-hexosaminidase
activity during chronic enteritis while having no effect in the
normal intestine.normal; 3.1 ± 0.5 in inflamed; 14.3 ± 2.2 in normal + ketoti-
fen and 14 ± 2.3 in inflamed ± ketotifen). In contrast, in
crypt cells Na-K-ATPase activity was significantly increased
in the inflamed intestine, but this was also reversed by keto-
tifen (Figure 3B, 6.3 ± 1.8 nmol/mg protein•min in normal;
12.7 ± 1.3 in inflamed; 5.9 ± 1.1 in normal + ketotifen and
7.4 ± 0.8 in inflamed + ketotifen).
Effect of ketotifen on Na-glutamine co-transport in villus
and crypt cell BBMV
While changes in Na-K-ATPase activity might be partially
responsible for co-transporter alterations at the cellular
level, it is important to determine whether mast cell media-
tors have any effect at the level of the co-transporters in
the BBM. Ketotifen treatment of rabbits with chronic intes-
tinal inflammation resulted in a significant reversal of
Na-glutamine co-transport uptake in villus cell BBMV
(Figure 4A, Na-glutamine co-transport in villus BBMV: in
normal 133 ± 3.5 pmol/mg protein•30 sec, in chronically
inflamed 39.1 ± 3.6, in normal + ketotifen 135 ± 1.7 and in
inflamed + ketotifen 142 ± 9.2). It also reversed the stimu-
lation of Na-glutamine co-transport in crypt cell BBMV
Figure 3 Effect of ketotifen on Na-K-ATPase activity. A, Villus cells.
Na-K-ATPase activity that was significantly reduced in the villus cells
during chronic enteritis was reversed by ketotifen treatment. B, Crypt
cells. Na-K-ATPase activity was significantly elevated in the crypt cells
from the chronically inflamed intestine and this stimulation was
reversed by ketotifen treatment. Na-K-ATPase activity was unaffected
in the crypt cells from normal intestine.
Figure 4 Effect of ketotifen on Na-glutamine co-transport in BBMV.
A, Villus cells. Na-dependent glutamine uptake was significantly
decreased in villus cell BBMV from the chronically inflamed intestine
and this inhibition was reversed with ketotifen treatment. B, Crypt
cells. Na-dependent glutamine uptake was significantly increased in
crypt cell BBMV during chronic intestinal inflammation and this
stimulation was reversed by ketotifen treatment.
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normal 34.3 ± 2 pmol/mg protein•90 sec, in chronically
inflamed 136 ± 7.7, normal + ketotifen 41.6 ± 2.5, and in
inflamed + ketotifen 44 ± 2.6).
These results indicate that mast cell stabilization re-
versed the inhibition of Na-glutamine co-transport in
villus cell BBMV, and stimulation in crypts cell BBMV at
the level of the BBM co-transporter.Table 1 Kinetic parameters of Na-glutamine co-transport
in villus cell BBMV
Vmax (nmol/mg protein•6 sec) Km (mM)
Control 3.4 ± 0.1 24 ± 1.5
Inflamed 1.7 ± 0.03* 27.1 ± 1.1
Inflamed + ketotifen 3.2 ± 0.1* 23.7 ± 1.9
In villus cells, the maximal rate of uptake (Vmax) of Na-glutamine co-transport
which was significantly diminished in chronically inflamed intestine was
reversed by ketotifen treatment (n = 3, *p < 0.01).Kinetic studies
To determine the mechanism of alterations of the BBM
glutamine co-transporters by ketotifen in inflamed villus
and crypt cells, we performed BBMV kinetic studies. As the
concentration of extra-vesicular glutamine was increased,
glutamine uptake was stimulated and subsequently became
saturated in all conditions. Kinetic parameters showed that
ketotifen reversed the inhibition of B0AT1 in villus cells by
restoring the Vmax without affecting the affinity of the co-
transporter (Table 1; Vmax for glutamine uptake in BBMV
was 3.4 ± 0.1 pmol/mg protein•6 sec in normal, 1.7 ± 0.03
in inflamed and 3.2 ± 0.1 in inflamed + ketotifen).
In contrast, kinetic studies showed that ketotifen re-
versed the affinity of SN2/SNAT5, which was increased
during chronic inflammation, without altering the max-
imal rate of uptake of glutamine (Table 2; Km for glu-
tamine uptake in crypt BBMV was 49.6 ± 4.8 mM innormal, 21.2 ± 0.4.3 in inflamed and 45 ± 0.6 in inflamed +
ketotifen).
Thus, this data demonstrated that the mechanism of
ketotifen mediated reversal of inhibition of B0AT1 activity
in the villus cells from the chronically inflamed intestine
was by the restoration of the number of co-transporters in
the BBM. Whereas, the reversal of stimulation of SN2/
SNAT5 activity in crypt cells by ketotifen was secondary to
the restoration of the affinity of the co-transporter for its
substrate.
Western blot analysis
Immunoreactive protein levels of B0AT1 and SN2/SNAT5
were determined in the villus and crypt cell BBM for all
experimental conditions. Figure 5 shows a representative
immunoblot of B0AT1 from villus cell BBM. Densitometric
analysis of relative protein expression revealed that ketotifen
Table 2 Kinetic parameters of Na-glutamine co-transport
in crypt cell BBMV
Vmax (nmol/mg protein•6 sec) Km (mM)
Control 2.4 ± 0.9 49.6 ± 4.8
Inflamed 2.6 ± 0.4 21.2 ± 4.3*
Inflamed + ketotifen 2.3 ± 0.6 45 ± 0.6*
In crypt cells, the affinity (Km) of Na-glutamine co-transport which was in-
creased significantly during chronic intestinal inflammation was reversed back
to its normal levels by ketotifen treatment (n = 3, *p < 0.01).
Figure 6 SN2/SNAT5 protein expression in crypt cell BBM. A
representative Western blot of BBM SN2/SNAT5 protein levels is
shown in the upper panel. In the lower panel densitometric
quantitation is shown. The levels of BBM SN2/SNAT5 protein
expression remained unaltered in all experimental conditions (n = 4).
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lus cell BBM from the chronically inflamed intestine and did
not have any effect on the protein levels in the normal villus
BBM. Figure 6 is a representative immunoblot of crypt cell
BBM SN2/SNAT5 from all experimental conditions. Densi-
tometric quantitation showed that the relative protein ex-
pression of SN2/SNAT5 was unchanged in the BBM of crypt
cells from all experimental conditions.
This data in conjunction with the kinetic analysis above
demonstrates that the mechanism of ketotifen mediated re-
versal of Na-glutamine co-transport during chronic intes-
tinal inflammation is through the restoration of the B0AT1
numbers in villus and affinity of SN2/SNAT5 in crypt cells.
Discussion
It is well documented that glutamine is an important nu-
trient required for the normal growth and differentiation
of intestinal enterocytes [23,24]. Therefore, glutamine be-
comes more important to help restore the mucosal integ-
rity and function of the small intestinal mucosa in chronicFigure 5 B0AT1 protein expression in villus cell BBM. A representative
Western blot of BBM B0AT1 protein levels is shown in the upper panel.
In the lower panel densitometric quantitation is shown. The relative
protein expression of B0AT1 that was reduced during chronic intestinal
inflammation was restored to near-normal levels by ketotifen treatment
and remained unaffected in the normal intestine.pathophysiological conditions [23]. There are two different
Na dependent co-transport pathways that enable glutam-
ine absorption in the rabbit intestine, namely B0AT1 in
villus and SN2/SNAT5 in crypt cells [7,8]. It has been
shown previously that B0AT1 is inhibited in villus during
chronic intestinal inflammation, whereas SN2/SNAT5 is
stimulated in crypt cells [9] and treatment with a broad
spectrum immune modulator reversed these alterations
during chronic intestinal inflammation [19]. In the chron-
ically inflamed intestine, mast cells have been shown to be
important in the pathogenesis and progression of disease
[14,25]. However, the regulation of Na-glutamine co-
transporter alterations by mucosal mast cells during in-
testinal inflammation is not known. Therefore, the aim
of this study was to investigate the role of the mucosal
mast cells on Na-glutamine co-transport changes dur-
ing chronic intestinal inflammation.
In the present study, mast cell stabilization by ketotifen
reversed the inhibition of B0AT1 in intestinal villus during
chronic intestinal inflammation and the mechanism of re-
versal of inhibition was secondary to restoration of dimin-
ished co-transporter numbers in the villus cell BBM. The
mechanism of B0AT1 inhibition in the chronically inflamed
intestine, secondary to a reduction in co-transporter num-
bers in the villus cell BBM, appears to be unique to this
co-transporter. This is because other villus cell BBM
Na-amino acid and di-peptide transporters are affected
by a different mechanism during chronic intestinal in-
flammation. We have previously shown that Na-alanine
co-transport (mediated by ATB0) in villus BBM of the
rabbit small intestine is inhibited during chronic intes-
tinal inflammation, not secondary to alteration in the
number of BBM co-transporters, but secondary to a re-
duction in the affinity of the co-transporter for alanine
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(PEPT1) was also significantly diminished during chronic
intestinal inflammation and the mechanism of this inhib-
ition was again secondary to a reduction in the affinity of
the co-transporter rather than an alteration in the number
of co-transporters on the BBM of villus cells [18]. However,
a different class of Na-nutrient co-transporters, specifically,
Na-glucose co-transporter SGLT1, is inhibited during
chronic intestinal inflammation by a reduction in the num-
ber of BBM co-transporters [27].
Unlike villus cells, ketotifen reversed the stimulation
of SN2/SNAT5 in crypt cells and the mechanism of re-
versal was secondary to the restoration of the affinity
(Km) of the co-transporter for glutamine. SN2/SNAT5 is
the only Na-nutrient co-transporter that has been re-
ported to be present in the BBM of crypt cells from the
rabbit small intestine [8]. Numerous studies demonstrate
that Na-glucose [18] Na-alanine [17], Na-bile acid co-
transport [16] and PEPT1 [25] are present only in villus
cells, but not crypt cells in the rabbit intestine [16-18].
Thus, presence of Na-glutamine co-transport in crypt
cells further emphasizes the importance of this nutrient
for the well-being of intestinal epithelial cells. Further,
unlike all other Na-nutrient co-transport processes which
are inhibited during chronic intestinal inflammation
[16,18,28], only SN2/SNAT5 is stimulated so as to po-
tentially compensate for the inhibition of Na-glutamine
co-transport in villus cells [9]. Though the reversal of
Na-K-ATPase activity in ketotifen treated inflamed vil-
lus and crypt might appear to be partially responsible
for the reversal of B0AT1 and SN2 activities, BBMV
vesicle kinetic studies and Western Blot analyses sug-
gest that they are directly regulated by specific immune
inflammatory mediators. The differential mechanism of
regulation of Na-glutamine co-transport in crypt as
compared to villus, specifically, altered affinity of SN2/
SNAT5 during chronic intestinal inflammation sug-
gests that a specific immune inflammatory mediator/
pathway might be responsible for each Na-glutamine
co-transport alteration [29]. Activated mast cells are
known to generate and release abundant quantities of
preformed mediators such as tryptase, histamine, sero-
tonins, proteases, proteoglycans and cytokines such as
tumor necrosis factor α (TNFα) [30,31]. TNFα has been
shown to trigger multiple signaling pathways that regulate
innumerable target proteins. More specifically, it has been
shown to regulate several transcription factor proteins such
as nuclear factor kappa B and activating protein 1 [32]. In
the present study, alteration of the transcription factors by
TNFα activated signaling pathways, either by phos-
phorylation or dephosphorylation, might be responsible
for altered B0AT1 protein transcription. Mast cells also
release newly formed eicosanoids such as leukotriene
C4, prostaglandin (PG)D2, and leukotriene B4. Of these,PGD2 has been found to play a major role in the progres-
sion of intestinal inflammation and has been shown to acti-
vate G-protein coupled receptors DP1 and DP2 resulting in
the activation of adenylate cyclase and subsequent increase
in intracellular cAMP levels and subsequent activation
of the cAMP mediated protein kinase A (PKA) pathway
[33,34]. The PKA pathway might regulate B0AT1 in the
inflamed intestine by altering the phosphorylation status
of transcription factors that regulate B0AT1 transcription.
Similarly, PKA mediated direct phosphorylation of SN2
protein might be responsible for its altered affinity during
inflammation. Previously, our laboratory has shown that
an immune inflammatory mediator such as Leukotriene
D4 alters the affinity of a different BBM amino acid co-
transporter, specifically, Na-alanine co-transporter, ASCT1,
and that this alteration was due to secondary changes in
ASCT1 phosphorylation levels mediated by protein kinase
C pathway [29,35].
In the present study, since mast cell stabilization reversed
the increased affinity of SN2/SNAT5, as well as the inhibition
of B0AT1 in the chronically inflamed rabbit intestine, it is
reasonable to postulate that mast cell mediators function as
an upstream common immune modulator of Na-glutamine
co-transport alterations. Future studies are in order to deter-
mine the downstream immune inflammatory pathway/s and
the specific inflammatory mediator/s that might be respon-
sible for the regulation of Na-glutamine co-transporters
B0AT1 and SN2 during intestinal inflammation.
Conclusion
In conclusion, the uniquely altered Na-dependent glutam-
ine co-transporters, inhibition of B0AT1 in villus and
stimulation of SN2/SNAT5 in crypt cells, are regulated
back to normal by mast cell stabilization in the chronically
inflamed small intestine. The mechanisms of ketotifen me-
diated restoration of function are the same mechanisms
that resulted in their original alteration, specifically, dimin-
ished co-transporter numbers in villus and enhanced affin-
ity for glutamine in crypt cells during chronic intestinal
inflammation. These observations indicate that mast cells
likely function as an upstream broad-spectrum immune
modulator responsible for the unique regulation of B0AT1
in villus and SN2/SNAT5 in crypt cells during chronic in-
testinal inflammation.
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